NMDA antagonist

NMDA antagonist

Neurology Any of a number of agents that protect against brain damage in neurologic disorders–eg, stroke; PCP–phencyclidine and ketamine are effective, but have psychotomimetic effects or damage neurons in the cerebral cortex; diazepam and barbiturates act at the GABA receptor channel complex, and may prevent the unwanted side effects of NMDA antagonists
Mentioned in ?
References in periodicals archive ?
'The promising data from our previous exploratory Phase 2 trial showed significant improvements in Severe Impairment Battery (SIB) scores for patients in the 20-microg Bryostatin-1 dose group not on memantine, an NMDA antagonist. These results may indicate a potential reversal of disease progression in patients with moderate to severe AD, suggesting the potential to translate Bryostatin's neurorestorative properties into the clinic.
Another promising NMDA antagonist, rapastinel, is wending its way through clinical trials--but should it be approved, its use might be limited by the requirement for intravenous delivery.
Biohaven's low-trapping NMDA antagonist (BHV-5000) was in-licensed from AstraZeneca and potential development programs include Rett syndrome, treatment-resistant depression and chronic pain disorders.
Lastly, our oral, low-trapping NMDA antagonist, BHV-5000, is completing nonclinical and Phase 1 work to support later stage development.
Ketamine is an NMDA antagonist and it can potentially be used for the management of refractory status epilepticus (RSE).
Unlike other potent NMDA receptor targeting compounds, BHV-5000 is a NMDA antagonist that has not been associated with the prominent psychotomimetic effects and is orally bioavailable, concluded the company .
Our case report contributes to the relatively sparse literature describing NMDA antagonist therapy for treatment of core ASD symptomatology.
Therefore, they suggested withholding amantadine, an NMDA antagonist with some dopaminergic activity.
demonstrated that the NMDA antagonist dizocilpine maleate (MK801) could attenuate aminoglycoside-induced damage to SGNs and IHCs [15].
Memantine is another conventional nonselective NMDA antagonist used for the treatment of dementia.
Also worth noting is that ketamine, an NMDA antagonist which has emerged as an ultra-rapid acting antidepressant, is an anesthetic, suggesting that perhaps it may help mitigate the pain symptoms that often accompany major depression.